SoniVie, ReCor Move Forward With Ultrasound Renal Denervation Technologies
The FDA granted its breakthrough designation to SoniVie’s TIVUS and ReCor's Paradise ultrasound renal denervation systems for treating hypertension.
You may also be interested in...
Cardiovascular Catch-Up: Spring Brings Bloom Of New Clinical Trial Results And Launches
April and May were full of cardiovascular professional society conferences, yielding important new research results along with announcements of major new clinical trials. Here are a few of the highlights.
Breakthrough Pulmonary Hypertension Treatment To Enter Pivotal Trial Before Year End
IDE trial of SoniVie’s catheter device will be the first for a denervation treatment for PAH.
Approval Of Medtronic’s Renal Denervation System Delayed By COVID-19
Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.